Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
CSBR
Champions Oncology, Inc.
Company provides outsourced drug development and preclinical/clinical research services to biopharma (CRO-style).
|
$99.41M |
$7.17
+0.03%
|
|
XTNT
Xtant Medical Holdings, Inc.
Xtant operates as an OEM/contract manufacturer for orthobiologic and implant products.
|
$97.35M |
$0.73
-6.45%
|
|
KBLB
Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories produces recombinant spider silk proteins via transgenic silkworms, a core product category defined as Recombinant Proteins & Enzymes.
|
$97.28M |
$0.09
|
|
IPA
ImmunoPrecise Antibodies Ltd.
Core antibody discovery platform offering de novo antibody design and epitope mapping via LENSai/HYFT.
|
$95.54M |
N/A
|
|
ADAG
Adagene Inc.
Core focus on monoclonal antibody therapeutics (ADG126 and related SAFEbody-based antibodies).
|
$92.33M |
$1.96
+2.08%
|
|
ONCY
Oncolytics Biotech Inc.
Pelareorep is an oncolytic virus immunotherapy developed by Oncolytics Biotech, placing the company in Biotech - Oncology.
|
$91.91M |
$1.03
+6.37%
|
|
CBUS
Cibus, Inc.
Reported contract research revenue indicates direct R&D services provided to clients alongside platform licensing.
|
$91.66M |
$1.68
+5.66%
|
|
ADVM
Adverum Biotechnologies, Inc.
Lead program Ixo-vec is a gene therapy for an ocular indication, placing Adverum in the Biotech - Gene Therapy category.
|
$91.49M |
$4.38
+0.34%
|
|
COYA
Coya Therapeutics, Inc.
COYA's autologous regulatory T cell therapy program (COYA 101) represents a direct cell therapy product line.
|
$89.65M |
$5.36
-0.09%
|
|
CALC
CalciMedica, Inc.
CalciMedica's lead candidate Auxora is a CRAC channel inhibitor, i.e., an ion channel modulator.
|
$88.72M |
$5.77
+17.76%
|
|
CRDL
Cardiol Therapeutics Inc.
Cardiol Therapeutics' lead drug is a cardiovascular therapy targeting heart disease.
|
$87.64M |
$1.06
+10.59%
|
|
BHST
BioHarvest Sciences Inc. Common Stock
BioHarvest operates a CDMO division providing contract development and manufacturing services for plant-based compounds.
|
$84.59M |
$4.89
-4.12%
|
|
INO
Inovio Pharmaceuticals, Inc.
INO's core DNA medicines platform and lead candidate INO-3107 are gene therapy products based on DNA plasmids delivered via CELLECTRA; maps to gene therapy.
|
$84.50M |
$1.57
-0.94%
|
|
BMEA
Biomea Fusion, Inc.
Direct product category: Biomea Fusion is developing oral small molecule therapeutics, including icovamenib and BMF-650.
|
$83.91M |
$1.41
+1.08%
|
|
TIL
Instil Bio, Inc.
Instil Bio's lead candidate AXN-2510/IMM2510 is a bispecific antibody, placing the company squarely in the Bispecific Antibodies investable theme.
|
$82.97M |
$5.79
-52.89%
|
|
KRRO
Korro Bio, Inc.
KRRO's core offering is its OPERA oligonucleotide platform enabling RNA editing therapeutics (oligonucleotide-based editing).
|
$82.45M |
$8.78
-0.23%
|
|
ANVS
Annovis Bio, Inc.
The lead candidate Buntanetap is positioned as an Alzheimer's disease (AD) therapeutics program with cognition endpoints and an FDA-aligned path toward NDA filings.
|
$80.48M |
$4.17
+10.16%
|
|
LFVN
LifeVantage Corporation
LoveBiome's microbiome/gut-health focus expands into digestive-health supplement opportunities.
|
$80.46M |
$6.36
+0.47%
|
|
ATOS
Atossa Therapeutics, Inc.
Atossa is a clinical-stage biotech focused on oncology with Z-endoxifen as its lead cancer therapy candidate.
|
$79.72M |
$0.66
+7.68%
|
|
ACRV
Acrivon Therapeutics, Inc. Common Stock
Companion Diagnostics: The company develops the OncoSignature companion diagnostic to identify patients likely to respond to its therapies.
|
$79.58M |
$2.56
+1.19%
|
|
VOR
Vor Biopharma Inc.
Vor Biopharma is focused on engineered cell therapies (eHSCs) and trem-cel, a cell therapy product.
|
$79.24M |
$12.50
+3.05%
|
|
PLRX
Pliant Therapeutics, Inc.
Company's lead and mid-stage assets include oral small-molecule therapeutics (bexotegrast and PLN-101095) targeting integrin pathways.
|
$79.19M |
$1.29
+1.17%
|
|
SCLX
Scilex Holding Company
Core business focused on non-opioid pain management drugs and a pipeline of non-opioid therapies.
|
$78.88M |
$11.34
-1.05%
|
|
MNOV
MediciNova, Inc.
MN-166 (ibudilast) and MN-001 (tipelukast) are oral small-molecule therapeutics in MediciNova's development pipeline.
|
$78.47M |
$1.60
+1.58%
|
|
XBIT
XBiotech Inc.
Core products are monoclonal antibody therapeutics derived from the True Human platform.
|
$78.35M |
$2.58
+1.78%
|
|
IGMS
IGM Biosciences, Inc.
IGMS's engineered antibodies are monoclonal antibody therapeutics, a core product category.
|
$76.35M |
$1.27
|
|
EQ
Equillium, Inc.
Equillium's pipeline focuses on immunology/inflammatory diseases, aligning with Immunology Therapeutics.
|
$76.16M |
$1.20
-6.64%
|
|
VANI
Vivani Medical, Inc.
Vivani's NanoPortal is a proprietary drug-implant platform enabling ultra long-acting, localized drug delivery.
|
$74.65M |
$1.30
+3.17%
|
|
ENTX
Entera Bio Ltd.
Entera Bio's N-Tab platform is a drug-delivery platform enabling oral administration of large-molecule peptides.
|
$73.97M |
$1.63
+3.16%
|
|
ASRT
Assertio Holdings, Inc.
ROLVEDON and related oncology-supportive care products position Assertio in Biotech - Oncology as its growth drivers.
|
$73.66M |
$11.47
+3.05%
|
|
TENX
Tenax Therapeutics, Inc.
TNX-103 levosimendan is a cardiovascular drug candidate in Phase 3 for PH-HFpEF, making Cardiovascular Drugs the direct product category.
|
$73.23M |
$16.07
+1.10%
|
|
CLNN
Clene Inc.
Clene's proprietary clean-surfaced nanotechnology platform operates as a drug delivery platform for CNM-Au8.
|
$72.13M |
$7.22
|
|
CMPX
Compass Therapeutics, Inc.
Compass Therapeutics is an oncology-focused biotech developing cancer therapies, anchoring its business in oncology.
|
$71.97M |
$5.69
-1.90%
|
|
CPIX
Cumberland Pharmaceuticals Inc.
DMD cardiomyopathy orphan/rare pediatric disease designations place the pipeline in the rare diseases biotech space.
|
$69.56M |
$4.68
-1.68%
|
Showing page 17 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
